Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ledispavir / sofosbuvir (Harvoni®) cannot be endorsed for use within NHS Wales for the treatment of chronic hepatitis C in adolescents aged 12 to < 18 years. |
||
|
||
Medicine details |
||
| Medicine name | ledispavir/sofosbuvir (Harvoni®) | |
| Formulation | 90 mg/400 mg film-coated tablet | |
| Reference number | 3556 | |
| Indication | Ttreatment of chronic hepatitis C in adolescents aged 12 to < 18 years. |
|
| Company | Gilead Sciences Ltd | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 26/10/2017 | |